Skip to main content
Premium Trial:

Request an Annual Quote

Three RNAi-Related Patent Applications Published by the USPTO: Nov 18, 2005

Premium

Title: Lentiviral Vectors, Related Reagents, and Methods of Use Thereof

Number: 20050251872

Filed: Sept. 5, 2003

Lead Inventor: James Bear, University of North Carolina Chapel Hill School of Medicine

The invention, the patent application's abstract states, "provides new lentiviral vectors, including lentiviral transfer plasmids and infectious lentiviral particles. Lentiviral vectors of the invention were designed to offer a number of desirable features including reduced size, convenient cloning sites (including multiple cloning sites and sites for particularly useful restriction enzymes), loxP sites, self-inactivating LTRs, etc."

The abstract states that "certain of the vectors are optimized for expression of reporter genes and/or for expression of siRNAs or shRNAs within eukaryotic cells. The invention also provides three- and four-plasmid lentiviral expression systems. In addition, the invention provides a variety of methods for using the vectors including gene silencing in cells and transgenic animals, and methods of treating disease."


Title: FcγRIIA-Specific Nucleic Acid Interference

Number: 20050250722

Filed: Nov. 15, 2004

Lead Inventor: Diana Beardsley, Yale University School of Medicine

"The … invention provides methods and compositions for attenuating expression of Fc.gamma.RIIA," the patent application's abstract states. "In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence."


Title: Gene Knock Down by Intracellular Expression of Aptamers

Number: 20050250106

Filed: April 23, 2004

Lead Inventor: David Epstein, Archemix

"Materials and methods are provided for target validation by gene knock-down with intracellularly expressed aptamers and siRNAs," the patent application's abstract states. "The aptamers produced by the materials and methods of the invention are useful in target validation for therapeutics development."

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.